A study to assess the effect of surovatamig in adult participants with antibody-mediated kidney disease

Trial Identifier: D740FC00001
Sponsor: AstraZeneca
Start Date: March 2026
Primary Completion Date: April 2028
Study Completion Date: October 2029

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
DE Düsseldorf, DE, 40225
ES Barcelona, ES, 08025
ES Madrid, ES, 28041
FR Bordeaux, FR, 33076
FR Creteil, FR, 94010
FR Lyon, FR, 69009
FR Nantes, FR, 44093
FR Nîmes Cedex 9, FR, 30029
IT Brescia, IT, 25123
IT Rozzano, IT, 20089
IT Torino, IT, 10154
PL Łódź, PL, 92-213
US, CA Los Angeles, CA, US, 90095
US, IA Iowa City, IA, US, 52242
US, MD Bethesda, MD, US, 20889
US, NY New York, NY, US, 10016
US, TX Houston, TX, US, 77027
US, TX Houston, TX, US, 77030